As MDSCs from TLR4KO mice failed to produce IL-10 and were less effective in reducing macrophage production of IL-12, the TLR4 pathway in MDSCs was considered a promising therapeutic target for promoting anti-tumor immune responses56. This evidence concerns the gene TLR4 and neoplasm.